Skip to main content
Top
Published in: Cancer Cell International 1/2014

Open Access 01-12-2014 | Primary research

Sorting and identification of side population cells in the human cervical cancer cell line HeLa

Authors: Wenjuan Qi, Chao Zhao, Lijun Zhao, Ning Liu, Xiaoping Li, Weidong Yu, Lihui Wei

Published in: Cancer Cell International | Issue 1/2014

Login to get access

Abstract

Background

Several reports have revealed that cancer stem cells (CSCs) exist in many types of solid tumors. Some studies have demonstrated that side population (SP) cells isolated from diverse cancer lines harbor cancer stem-like properties, but there are few reports examining the characteristic of SP cells in human cervical cancer. The aim of this study is 1) to find out a feasible way to detect the tumor stem-like cells in cervical cancer, and 2) to analyze the properties of the SP cells being sorted.

Methods

Isolated SP and non-SP cells from human cervical cancer cell line Hela by Hoechst 33342 dying method and flow cytometry analysis. Observing morphology of SP and non-SP cells. The expression of various biomarkers putatively related to cancer stem cells were investigated by immucytochemistry of SP and non-SP cells. We also analyzed cell cycle and cell apoptosis for sorted cells. The oncogenicity of the SP and non-SP cells were analyzed by tumor formation in nonobesediabeti- c/severe combined immune- deficient (NOD/SCID) mice. The drug-resistant and radiation-resistant index between SP, non-SP and Hela cells was estimated by MTS assay.

Results

The fraction of SP cells in Hela was approximately 1.07 ± 0.32%. SP cells were smaller and rounder in shape than non-SP cells, and mostly showed colony-like growth. Immunocytochemistry showed that stem cell makers (Oct3/4, CD133, BCRP) were highly expressed in SP cells. Moreover, the number of apoptotic cells among non-SP cells (17.6 ± 3.7%) was significantly higher compared with that among SP cells (4.4 ± 1.2%). The HE staining of in vivo grown tumors result from SP cells showed more poor differentiation, though no significant differences were shown between SP and non-SP cells in NOD/SCID mice tumorigenicity. Furthermore, SP cells demonstrated a higher degree of drug resistance against trichostatin A (TSA) compared with that of non-SP and Hela cells. SP cells were also found to be more resistant against radiotherapy.

Conclusions

SP cells possess some characteristics of CSCs, namely high proliferation ability, chemoresistance and radioresistance, which may be helpful to elucidate novel targets for effective clinical treatments of cervical cancer in the future.
Appendix
Available only for authorised users
Literature
1.
go back to reference Reya T, Morrison SJ, Clarke MF, Weissman IL: Stem cells, cancer, and cancer stem cells. Nature. 2001, 414: 105-111. 10.1038/35102167.CrossRefPubMed Reya T, Morrison SJ, Clarke MF, Weissman IL: Stem cells, cancer, and cancer stem cells. Nature. 2001, 414: 105-111. 10.1038/35102167.CrossRefPubMed
2.
go back to reference Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003, 100: 3983-3988. 10.1073/pnas.0530291100.CrossRefPubMedCentralPubMed Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003, 100: 3983-3988. 10.1073/pnas.0530291100.CrossRefPubMedCentralPubMed
3.
go back to reference Goodell MABK, Paradis G, Conner AS, Mulligan RC: Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med. 1996, 183: 1797-1806. 10.1084/jem.183.4.1797.CrossRefPubMed Goodell MABK, Paradis G, Conner AS, Mulligan RC: Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med. 1996, 183: 1797-1806. 10.1084/jem.183.4.1797.CrossRefPubMed
4.
go back to reference Wulf GG, Wang RY, Kuehnle I, Weidner D, Marini F, Brenner MK: A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid 1eukemia. Blood. 2001, 98: 1166-1173. 10.1182/blood.V98.4.1166.CrossRefPubMed Wulf GG, Wang RY, Kuehnle I, Weidner D, Marini F, Brenner MK: A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid 1eukemia. Blood. 2001, 98: 1166-1173. 10.1182/blood.V98.4.1166.CrossRefPubMed
5.
go back to reference Setoguchi T, Taga T, Kondo T: Cancer stem cells persist in many cancer cell lines. Cell Cycle. 2004, 3: 414-415. 10.4161/cc.3.4.799.CrossRefPubMed Setoguchi T, Taga T, Kondo T: Cancer stem cells persist in many cancer cell lines. Cell Cycle. 2004, 3: 414-415. 10.4161/cc.3.4.799.CrossRefPubMed
6.
go back to reference Chiba T, Kita K, Zheng YW, Yokosuka O, Iwama A, Nakauchi H: Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology. 2006, 44: 240-251.CrossRefPubMed Chiba T, Kita K, Zheng YW, Yokosuka O, Iwama A, Nakauchi H: Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology. 2006, 44: 240-251.CrossRefPubMed
7.
go back to reference Hu L, McArthur C, Jaffe RB: Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant. Br J Cancer. 2010, 102: 1276-1283. 10.1038/sj.bjc.6605626.CrossRefPubMedCentralPubMed Hu L, McArthur C, Jaffe RB: Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant. Br J Cancer. 2010, 102: 1276-1283. 10.1038/sj.bjc.6605626.CrossRefPubMedCentralPubMed
8.
go back to reference Ho MM, Ng AV, Lam S, Hung JY: Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res. 2007, 67: 4827-4833. 10.1158/0008-5472.CAN-06-3557.CrossRefPubMed Ho MM, Ng AV, Lam S, Hung JY: Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res. 2007, 67: 4827-4833. 10.1158/0008-5472.CAN-06-3557.CrossRefPubMed
9.
go back to reference Zhang SN, Huang FT, Huang YJ, Zhong W, Yu Z: Characterization of a cancer stem cell-like side population derived from human pancreatic adenocarcinoma cells. Tumori. 2010, 96: 985-992.PubMed Zhang SN, Huang FT, Huang YJ, Zhong W, Yu Z: Characterization of a cancer stem cell-like side population derived from human pancreatic adenocarcinoma cells. Tumori. 2010, 96: 985-992.PubMed
10.
go back to reference Hadnagy A, Gaboury L, Beaulieu R, Balicki D: SP analysismay be used to identify cancer stem cell populations. Exp Cell Res. 2006, 312: 3701-3710. 10.1016/j.yexcr.2006.08.030.CrossRefPubMed Hadnagy A, Gaboury L, Beaulieu R, Balicki D: SP analysismay be used to identify cancer stem cell populations. Exp Cell Res. 2006, 312: 3701-3710. 10.1016/j.yexcr.2006.08.030.CrossRefPubMed
11.
go back to reference Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK: A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA. 1998, 95: 15665-15670. 10.1073/pnas.95.26.15665.CrossRefPubMedCentralPubMed Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK: A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA. 1998, 95: 15665-15670. 10.1073/pnas.95.26.15665.CrossRefPubMedCentralPubMed
12.
go back to reference Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ: The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med. 2001, 7: 1028-1034. 10.1038/nm0901-1028.CrossRefPubMed Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ: The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med. 2001, 7: 1028-1034. 10.1038/nm0901-1028.CrossRefPubMed
13.
go back to reference Bonnet D, Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997, 3: 730-737. 10.1038/nm0797-730.CrossRefPubMed Bonnet D, Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997, 3: 730-737. 10.1038/nm0797-730.CrossRefPubMed
14.
go back to reference Kondo T, Setoguchi T, Taga T: Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci USA. 2004, 101: 781-786. 10.1073/pnas.0307618100.CrossRefPubMedCentralPubMed Kondo T, Setoguchi T, Taga T: Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci USA. 2004, 101: 781-786. 10.1073/pnas.0307618100.CrossRefPubMedCentralPubMed
15.
go back to reference Haraguchi N, Utsunomiya T, Inoue H, Tanaka F, Mimori K, Barnard GF: Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells. 2006, 24: 506-513. 10.1634/stemcells.2005-0282.CrossRefPubMed Haraguchi N, Utsunomiya T, Inoue H, Tanaka F, Mimori K, Barnard GF: Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells. 2006, 24: 506-513. 10.1634/stemcells.2005-0282.CrossRefPubMed
16.
go back to reference Hischmann-jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U: A distinct"side population" of cells with high drug efflux capacity in huamn tumor cells. Proc Natl Acad Sci USA. 2004, 101: 142228-142233. Hischmann-jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U: A distinct"side population" of cells with high drug efflux capacity in huamn tumor cells. Proc Natl Acad Sci USA. 2004, 101: 142228-142233.
17.
go back to reference Huang D, Gao Q, Guo L, Zhang C, Jiang W, Li H: Isolation and identification of cancer stem-like cells in esophageal carcinoma cell lines. Stem Cells Dev. 2009, 18: 465-473. 10.1089/scd.2008.0033.CrossRefPubMed Huang D, Gao Q, Guo L, Zhang C, Jiang W, Li H: Isolation and identification of cancer stem-like cells in esophageal carcinoma cell lines. Stem Cells Dev. 2009, 18: 465-473. 10.1089/scd.2008.0033.CrossRefPubMed
18.
go back to reference Challen GA, Little MH: A Side Order of Stem Cells: The SP Phenotype. Stem Cells. 2006, 24: 3-12. 10.1634/stemcells.2005-0116.CrossRefPubMed Challen GA, Little MH: A Side Order of Stem Cells: The SP Phenotype. Stem Cells. 2006, 24: 3-12. 10.1634/stemcells.2005-0116.CrossRefPubMed
19.
go back to reference Yannamoto S, Kawasaki G, Yamada S, Yoshitomi I, Kawano T, Yonezawa H: Isolation and characterization of cancer stem-like side population cells in human oral cancer cells. Oral Oncol. 2011, 47: 855-860. 10.1016/j.oraloncology.2011.06.501.CrossRef Yannamoto S, Kawasaki G, Yamada S, Yoshitomi I, Kawano T, Yonezawa H: Isolation and characterization of cancer stem-like side population cells in human oral cancer cells. Oral Oncol. 2011, 47: 855-860. 10.1016/j.oraloncology.2011.06.501.CrossRef
20.
go back to reference Schmuck R, Warneke V, Behrens HM, Simon E, Weichert W, Rocken C: Genotypic and phenotypic characterization of side population of gastric cancer cell lines. Am J Pathol. 2011, 178: 1792-1804. 10.1016/j.ajpath.2010.12.043.CrossRefPubMedCentralPubMed Schmuck R, Warneke V, Behrens HM, Simon E, Weichert W, Rocken C: Genotypic and phenotypic characterization of side population of gastric cancer cell lines. Am J Pathol. 2011, 178: 1792-1804. 10.1016/j.ajpath.2010.12.043.CrossRefPubMedCentralPubMed
21.
go back to reference Doyle LA, Ross DD: Multidrug resistance mediated by the breast cancer resistance protein BCRP(ABCG2). Oncogene. 2003, 22: 7340-7358. 10.1038/sj.onc.1206938.CrossRefPubMed Doyle LA, Ross DD: Multidrug resistance mediated by the breast cancer resistance protein BCRP(ABCG2). Oncogene. 2003, 22: 7340-7358. 10.1038/sj.onc.1206938.CrossRefPubMed
22.
go back to reference Hu C, Li H, Li J, Zhu Z, Yin S, Hao X: Analysis of ABCG2 expression and side population identifies intrinsic drug efflux in the HCC cell line MHCC-97L and its modulation by Akt signaling. Carcinogenesis. 2008, 29: 2289-2297. 10.1093/carcin/bgn223.CrossRefPubMed Hu C, Li H, Li J, Zhu Z, Yin S, Hao X: Analysis of ABCG2 expression and side population identifies intrinsic drug efflux in the HCC cell line MHCC-97L and its modulation by Akt signaling. Carcinogenesis. 2008, 29: 2289-2297. 10.1093/carcin/bgn223.CrossRefPubMed
23.
go back to reference Moserle L, Ghisi M, Amadori A, Indraccolo S: Side population and cancer stem cell: therapeutic implications. Cancer letters. 2010, 288: 1-9. 10.1016/j.canlet.2009.05.020.CrossRefPubMed Moserle L, Ghisi M, Amadori A, Indraccolo S: Side population and cancer stem cell: therapeutic implications. Cancer letters. 2010, 288: 1-9. 10.1016/j.canlet.2009.05.020.CrossRefPubMed
24.
go back to reference Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M: ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007, 1: 555-567. 10.1016/j.stem.2007.08.014.CrossRefPubMedCentralPubMed Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M: ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007, 1: 555-567. 10.1016/j.stem.2007.08.014.CrossRefPubMedCentralPubMed
25.
go back to reference Jiang F, Qiu Q, Khanna A, Todd NW, Deepak J, Xing L, Wang H: Aldehyde dehydrogenase 1is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res. 2009, 7: 330-338. 10.1158/1541-7786.MCR-08-0393.CrossRefPubMedCentralPubMed Jiang F, Qiu Q, Khanna A, Todd NW, Deepak J, Xing L, Wang H: Aldehyde dehydrogenase 1is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res. 2009, 7: 330-338. 10.1158/1541-7786.MCR-08-0393.CrossRefPubMedCentralPubMed
26.
go back to reference Kim H, Lapointe J, Kaygusuz G, Ong DE, Li C, Van De Rijn M: The retinoic acid synthesis gene ALDH1a2 is a candidate tumor suppressor in prostate cancer. Cancer Res. 2005, 65: 8118-8124. 10.1158/0008-5472.CAN-04-4562.CrossRefPubMed Kim H, Lapointe J, Kaygusuz G, Ong DE, Li C, Van De Rijn M: The retinoic acid synthesis gene ALDH1a2 is a candidate tumor suppressor in prostate cancer. Cancer Res. 2005, 65: 8118-8124. 10.1158/0008-5472.CAN-04-4562.CrossRefPubMed
27.
go back to reference Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V: Identification of pancreatic cancer stem cells. Cancer Res. 2007, 6: 1030-1037.CrossRef Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V: Identification of pancreatic cancer stem cells. Cancer Res. 2007, 6: 1030-1037.CrossRef
28.
go back to reference Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U: A distinct “side population” of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA. 2004, 101: 14228-14233. 10.1073/pnas.0400067101.CrossRefPubMedCentralPubMed Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U: A distinct “side population” of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA. 2004, 101: 14228-14233. 10.1073/pnas.0400067101.CrossRefPubMedCentralPubMed
29.
go back to reference Chiba T, Kita K, Zheng YW, Yokosuka O, Saisho H, Iwama A: Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology. 2006, 44: 240-251.CrossRefPubMed Chiba T, Kita K, Zheng YW, Yokosuka O, Saisho H, Iwama A: Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology. 2006, 44: 240-251.CrossRefPubMed
30.
go back to reference Shi Y, Fu X, Hua Y, Han Y, Lu Y, Wang J: The side population in human lung cancer cell line NCI-H460 is enriched in stem-like cancer cells. PLoS One. 2012, 7: 1-8. Shi Y, Fu X, Hua Y, Han Y, Lu Y, Wang J: The side population in human lung cancer cell line NCI-H460 is enriched in stem-like cancer cells. PLoS One. 2012, 7: 1-8.
31.
go back to reference Wang J, Guo LP, Chen LZ, Zeng YX, Lu SH: Identification of cancer stem cell-like side population cells in human Nasopharygeal carcinoma cell line. Cancer Res. 2007, 67: 3716-3724. 10.1158/0008-5472.CAN-06-4343.CrossRefPubMed Wang J, Guo LP, Chen LZ, Zeng YX, Lu SH: Identification of cancer stem cell-like side population cells in human Nasopharygeal carcinoma cell line. Cancer Res. 2007, 67: 3716-3724. 10.1158/0008-5472.CAN-06-4343.CrossRefPubMed
32.
go back to reference Pan J, Zhang Q, Wang Y, You M: 26S proteasome activity is down-regulated in lung cancer stem-like cells propagated in vitro. Plos One. 2010, 5: 1-9. Pan J, Zhang Q, Wang Y, You M: 26S proteasome activity is down-regulated in lung cancer stem-like cells propagated in vitro. Plos One. 2010, 5: 1-9.
33.
go back to reference Platet N, Mayol J-F, Berger F, Herodin F, Wion D: Fluctuation of the SP/non-SP phenotype in the C6 glioma cell line. FEBS Letters. 2007, 581: 1435-1440. 10.1016/j.febslet.2007.02.071.CrossRefPubMed Platet N, Mayol J-F, Berger F, Herodin F, Wion D: Fluctuation of the SP/non-SP phenotype in the C6 glioma cell line. FEBS Letters. 2007, 581: 1435-1440. 10.1016/j.febslet.2007.02.071.CrossRefPubMed
34.
go back to reference Enokizono J, Kusuhara H, Sugiyama Y: Involvement of breast cancer resistance protein(BCRP/ABCG2) in the biliary excretion and intestinal efflux of troglitazone sulfate, the major metabolite of troglitazone with a cholestatic effect. Drug Metab Dispos. 2007, 35: 209-214.CrossRefPubMed Enokizono J, Kusuhara H, Sugiyama Y: Involvement of breast cancer resistance protein(BCRP/ABCG2) in the biliary excretion and intestinal efflux of troglitazone sulfate, the major metabolite of troglitazone with a cholestatic effect. Drug Metab Dispos. 2007, 35: 209-214.CrossRefPubMed
35.
go back to reference Xia P, Gou WF, Wang JJ, Niu ZF, Chen S, Takano Y: Distinct radiosensitivity of lung carcinoma stem-like side population and main population cells. Cancer Biother Radiopharm. 2013, 28: 471-478. 10.1089/cbr.2012.1388.CrossRefPubMed Xia P, Gou WF, Wang JJ, Niu ZF, Chen S, Takano Y: Distinct radiosensitivity of lung carcinoma stem-like side population and main population cells. Cancer Biother Radiopharm. 2013, 28: 471-478. 10.1089/cbr.2012.1388.CrossRefPubMed
36.
go back to reference Liang K, Jin W, Knuefermann C, Schmidt M, Mills GB, Ang KK: Targeting the phosphatidylinositol 3-kinase/Akt pathway for enhancing breast cancer cells toradiotherapy. Mol Cancer Ther. 2003, 2: 353-360.PubMed Liang K, Jin W, Knuefermann C, Schmidt M, Mills GB, Ang KK: Targeting the phosphatidylinositol 3-kinase/Akt pathway for enhancing breast cancer cells toradiotherapy. Mol Cancer Ther. 2003, 2: 353-360.PubMed
37.
go back to reference Zhang T, Cui GB, Zhang J, Zhang F, Zhou YA, Jiang T: Inhibition of PI3 kinases enhances the sensitivity of non-small cell lung cancer cells to ionizing radiation. Oncol Rep. 2010, 24: 1683-1689.PubMed Zhang T, Cui GB, Zhang J, Zhang F, Zhou YA, Jiang T: Inhibition of PI3 kinases enhances the sensitivity of non-small cell lung cancer cells to ionizing radiation. Oncol Rep. 2010, 24: 1683-1689.PubMed
38.
go back to reference Fujiwara K, Iwado E, Mills GB, Sawaya R, Kondo S, Kondo Y: Akt inhibitor shows anticancer and radiosensitizing effects in maligant glioma cells by inducingautohagy. Int J Oncol. 2007, 31: 753-760.PubMed Fujiwara K, Iwado E, Mills GB, Sawaya R, Kondo S, Kondo Y: Akt inhibitor shows anticancer and radiosensitizing effects in maligant glioma cells by inducingautohagy. Int J Oncol. 2007, 31: 753-760.PubMed
Metadata
Title
Sorting and identification of side population cells in the human cervical cancer cell line HeLa
Authors
Wenjuan Qi
Chao Zhao
Lijun Zhao
Ning Liu
Xiaoping Li
Weidong Yu
Lihui Wei
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2014
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/1475-2867-14-3

Other articles of this Issue 1/2014

Cancer Cell International 1/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine